And because retatrutide is not FDA-approved, there is no standardized dosing schedule, no prescription oversight, and no medical supervision
Emerging research is indicating that these meds may also create dysbiosis
Core compounds include: Retatrutide from $39.99, Tirzepatide from $54.99, MOTS-C from $69.99, Epitalon from $59.99, GHK-Cu from $29.99, Semax at $42.99, Selank at $32.99, BPC-157 from $49.99, TB-500 from $44.99, KPV at $35.99, PT-141 at $29.99, AOD-9604 at $39.99, and bacteriostatic water at $19.99
Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
This is consistent with other new peptide therapeutics
Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus